文献速递泌尿男性生殖肿瘤

STAMPEDE平台直接随机比较:长期激素治疗联合阿比特龙或多西他赛治疗前列腺癌

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
PubMed 文献 · Ann Oncol · 2018-01-01

STAMPEDE平台协议在2011年11月至2013年3月间直接随机比较了标准治疗(SOC)联合多西他赛(DocP)与SOC联合阿比特龙(AAP)在高危局部晚期或转移性前列腺癌患者中的疗效。共566例患者随机分配(SOC+DocP 189例,SOC+AAP 377例),中位随访4年,149例死亡。两组总生存无显著差异(HR=1.16,95%CI 0.82-1.65),无失败生存(HR=0.51)和无进展生存(HR=0.65) favoring SOC+AAP,但无转移生存和前列腺癌特异性生存无差异,症状性骨骼事件无差异;≥3级不良事件比例相似但毒性谱不同。

要点

  • SOC+AAP与SOC+DocP总生存无显著差异(HR=1.16,95%CI 0.82-1.65)。
  • SOC+AAP组无失败生存(HR=0.51)和无进展生存(HR=0.65)优于SOC+DocP组。
  • 两组≥3级不良事件比例相似(36% vs 40%),但毒性类型不同。

核心结论

  • 在高危局部晚期或转移性前列腺癌开始长期ADT的患者中,SOC+AAP与SOC+DocP的总生存和前列腺癌特异性生存无显著差异。
  • SOC+AAP组无失败生存和无进展生存优于SOC+DocP组,但症状性骨骼事件无差异。
  • 两组最差毒性分级总体相似,但毒性谱不同。

研究设计与样本

  • STAMPEDE多臂多阶段平台随机对照协议,直接随机比较SOC+DocP与SOC+AAP。
  • 2011年11月至2013年3月重叠招募,共566例患者随机分配:SOC+DocP 189例,SOC+AAP 377例。
  • SOC为长期ADT,多数非转移病例接受ADT≥2年及原发肿瘤放疗。
  • 分层随机分配比例2:1:2至SOC、SOC+多西他赛75 mg/m2每3周×6+泼尼松龙10 mg每日、SOC+阿比特龙1000 mg+泼尼松龙5 mg每日。
  • 主要终点为任何原因死亡,采用Cox比例风险模型和灵活参数模型分析,调整分层因素;非正式效能比较。

主要发现

  • 患者特征:342例(60%)M1,429例(76%)Gleason 8-10,449例(79%)WHO体能状态0,中位年龄66岁,中位PSA 56 ng/ml。
  • 中位随访4年,报告149例死亡。
  • 总生存HR=1.16(95%CI 0.82-1.65);无失败生存HR=0.51(95%CI 0.39-0.67);无进展生存HR=0.65(95%CI 0.48-0.88);无转移生存HR=0.77(95%CI 0.57-1.03);前列腺癌特异性生存HR=1.02(95%CI 0.70-1.49);症状性骨骼事件HR=0.83(95%CI 0.55-1.25)。
  • 安全性人群中,SOC+DocP组报告≥1次3级、4级、5级不良事件的比例分别为36%、13%、1%;SOC+AAP组分别为40%、7%、1%;两组1年和2年时点患病率均为11%。

临床怎么用

  • 对于开始长期ADT的高危局部晚期或转移性前列腺癌患者,SOC+AAP与SOC+DocP均为可选治疗标准,总生存获益相似。
  • 选择方案时需考虑毒性谱差异,根据患者合并症和耐受性个体化决定。
  • SOC+AAP在无失败生存和无进展生存方面可能更优,但需结合其他终点综合判断。

局限性

  • 该比较非正式效能设计,样本量有限(566例),可能不足以检测总生存的微小差异。
  • 中位随访4年相对较短,长期生存差异可能尚未完全显现。
  • 复发治疗模式在两组间不同,可能影响后续结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation of drug efficacy: a multi-arm multi-stage platform randomised controlled protocol recruiting patients with high-risk locally advanced or metastatic PCa starting long-term androgen deprivation therapy (ADT). The protocol provides the only direct, randomised comparative data of SOC + AAP versus SOC + DocP. METHOD: Recruitment to SOC + DocP and SOC + AAP overlapped November 2011 to March 2013. SOC was long-term ADT or, for most non-metastatic cases, ADT for ≥2 years and RT to the primary tumour. Stratified randomisation allocated pts 2 : 1 : 2 to SOC; SOC + docetaxel 75 mg/m2 3-weekly×6 + prednisolone 10 mg daily; or SOC + abiraterone acetate 1000 mg + prednisolone 5 mg daily. AAP duration depended on stage and intent to give radical RT. The primary outcome measure was death from any cause. Analyses used Cox proportional hazards and flexible parametric models, adjusted for stratification factors. This was not a formally powered comparison. A hazard ratio (HR) <1 favours SOC + AAP, and HR > 1 favours SOC + DocP. RESULTS: A total of 566 consenting patients were contemporaneously randomised: 189 SOC + DocP and 377 SOC + AAP. The patients, balanced by allocated treatment were: 342 (60%) M1; 429 (76%) Gleason 8-10; 449 (79%) WHO performance status 0; median age 66 years and median PSA 56 ng/ml. With median follow-up 4 years, 149 deaths were reported. For overall survival, HR = 1.16 (95% CI 0.82-1.65); failure-free survival HR = 0.51 (95% CI 0.39-0.67); progression-free survival HR = 0.65 (95% CI 0.48-0.88); metastasis-free survival HR = 0.77 (95% CI 0.57-1.03); prostate cancer-specific survival HR = 1.02 (0.70-1.49); and symptomatic skeletal events HR = 0.83 (95% CI 0.55-1.25). In the safety population, the proportion reporting ≥1 grade 3, 4 or 5 adverse events ever was 36%, 13% and 1% SOC + DocP, and 40%, 7% and 1% SOC + AAP; prevalence 11% at 1 and 2 years on both arms. Relapse treatment patterns varied by arm. CONCLUSIONS: This direct, randomised comparative analysis of two new treatment standards for hormone-naïve prostate cancer showed no evidence of a difference in overall or prostate cancer-specific survival, nor in other important outcomes such as symptomatic skeletal events. Worst toxicity grade over entire time on trial was similar but comprised different toxicities in line with the known properties of the drugs. TRIAL REGISTRATION: Clinicaltrials.gov: NCT00268476.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018. PMID: 29529169. doi:10.1093/annonc/mdy072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。